SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001213900-24-010560
Filing Date
2024-02-06
Accepted
2024-02-06 16:15:16
Documents
1
Group Members
GUY LEVYSOLEUS CAPITAL GROUP, LLCSOLEUS CAPITAL MASTER FUND, L.P.SOLEUS CAPITAL, LLCSOLEUS PE GP III, LLCSOLEUS PRIVATE EQUITY GP III, LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO SCHEDULE 13G ea192956-13ga1soleus3_har.htm SC 13G/A 155472
  Complete submission text file 0001213900-24-010560.txt   157331
Mailing Address 611 GATEWAY BOULEVARD, SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 400 SOUTH SAN FRANCISCO CA 94080 (650) 443-7400
Harpoon Therapeutics, Inc. (Subject) CIK: 0001708493 (see all company filings)

IRS No.: 473458693 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-90935 | Film No.: 24600448
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 104 FIELD POINT ROAD, 2ND FLOOR GREENWICH CT 06830
Business Address 104 FIELD POINT ROAD, 2ND FLOOR GREENWICH CT 06830 475-208-3178
Soleus Private Equity Fund III, L.P. (Filed by) CIK: 0001955982 (see all company filings)

IRS No.: 880637097 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A